QDEL, US2197981051

J.P. Morgan kept a Sell rating and USD 12.00 target for QuidelOrtho stock

Published on 10/20/2026 at 19:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 630.90 million in the quarter ended June 28, 2026, up 2.00 percent. QuidelOrtho stock costs EUR 12.70 on October 20, 2026.

Reporting date November 3, 2026

J.P. Morgan maintained a Sell rating and a USD 12.00 target on October 14, 2026.
Second-quarter revenue reached USD 630.90 million, up 2.00 percent year over year.
QuidelOrtho stock costs EUR 12.70 at Lang & Schwarz on October 20, 2026 at 7:39 p.m. CEST.
Third-quarter results are scheduled for November 3, 2026, after the Nasdaq close.

QDEL, US2197981051, Illustration mit AI erstellt.

J.P. Morgan maintained a Sell rating and set a USD 12.00 price target for QuidelOrtho on October 14, 2026, according to Markets Insider. QuidelOrtho stock was trading at EUR 12.70 at Lang & Schwarz on October 20, 2026 at 7:39 p.m. CEST.

Quarterly revenue reached USD 630.90 million

QuidelOrtho reported USD 630.90 million in second-quarter 2026 revenue, up 2.00 percent year over year. The company posted a GAAP net loss of USD 92.90 million for the quarter ended June 28, 2026, compared with a USD 255.40 million loss in the prior-year quarter, according to Markets Insider.

The second-quarter adjusted EBITDA reached USD 129.00 million, up 21.00 percent, while adjusted EBITDA margin expanded to 20.00 percent. Revenue outside China rose 6.00 percent year over year, but China revenue declined 23.00 percent, according to Benzinga.

Where does the price stand?

On Nasdaq, QDEL last traded at USD 14.25 on October 20, 2026 at 1:43 p.m. EDT while the session was open. The quoted 52-week Nasdaq range was USD 9.92 to USD 35.58, placing the stock well below its yearly high and above its yearly low.

QuidelOrtho's market capitalization was USD 977.1 million on October 20, 2026. The company operates in healthcare and medical specialties, developing diagnostic products for point-of-care testing, laboratories, molecular diagnostics and transfusion medicine.

What comes before the next report?

QuidelOrtho announced on October 20, 2026 that it will release third-quarter 2026 results on November 3, 2026, shortly after the Nasdaq close. The company scheduled its conference call for 5:00 p.m. ET, as reported by Nasdaq.

For the coming report, the key comparison is the gap between consolidated growth and the stronger result outside China. The second-quarter revenue increase was 2.00 percent overall, while revenue outside China grew 6.00 percent and China revenue fell 23.00 percent.

QuidelOrtho stock and the next catalyst

The USD 12.00 J.P. Morgan target sits below the Nasdaq price of USD 14.25 cited above, while the six-broker consensus target was USD 13.62 on October 19, 2026. That mix leaves the November report as the next dated point for investors assessing China demand, respiratory testing and cash conversion.

The further course of trading is shown by the continuously updated real-time quote of QuidelOrtho stock.